LAG 525

Drug Profile

LAG 525

Alternative Names: Anti-LAG-3-monoclonal-antibody - Novartis Oncology; LAG525

Latest Information Update: 07 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis Oncology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD223 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 10 Jun 2015 Preclinical trials in Solid tumours in Switzerland (unspecified route)
  • 10 Jun 2015 Novartis plans a phase Ib/II trial for Solid tumours (Late-stage disease) in USA, Australia, Canada and Singapore (NCT02460224)
  • 01 Jun 2015 Phase-I/II clinical trials in Solid tumours (Monotherapy, Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, Singapore, Canada, Belgium, USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top